R&D | December 12, 2025
OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases
The companies aim to expand treatment options for millions living with metabolic disorders
The companies aim to expand treatment options for millions living with metabolic disorders
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The company had achieved the highest "A" rating in Climate Change
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The product will be marketed by Dr. Reddy's Laboratories Inc.
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The company will respond to the US FDA within the stipulated timelines
Subscribe To Our Newsletter & Stay Updated
